Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Equity

v3.23.1
Condensed Consolidated Statements of Equity - USD ($)
shares in Thousands, $ in Thousands
Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Other Comprehensive Loss [Member]
Accumulated Deficit [Member]
Noncontrolling Interest [Member]
Total
Balance at Jun. 30, 2021   $ 9 $ 282,266 $ (63) $ (173,627) $ (17) $ 108,568
Balance (in shares) at Jun. 30, 2021   8,715          
Exercise of stock options     77       77
Exercise of stock options (in shares)   3          
Share-based compensation     821       821
Unrealized gain (loss) on available-for-sale debt securities       (1)     (1)
Net loss         (8,939)    
Net loss attributable to noncontrolling interest           (1)  
Net loss including portion attributable to noncontrolling interest             (8,940)
Balance at Sep. 30, 2021   $ 9 283,164 (64) (182,566) (18) 100,525
Balance (in shares) at Sep. 30, 2021   8,718          
Balance at Jun. 30, 2021   $ 9 282,266 (63) (173,627) (17) 108,568
Balance (in shares) at Jun. 30, 2021   8,715          
Common stock issued - RubrYc transaction             0
Net loss including portion attributable to noncontrolling interest             (33,250)
Balance at Mar. 31, 2022   $ 9 286,441 (194) (206,876)   79,380
Balance (in shares) at Mar. 31, 2022   8,726          
Balance at Sep. 30, 2021   $ 9 283,164 (64) (182,566) (18) 100,525
Balance (in shares) at Sep. 30, 2021   8,718          
Vesting of RSU's (in shares)   4          
Warrant issued for Transaction     967       967
Acquisition of remaining portion of iBio CDMO     (68)     $ 18 (50)
Share-based compensation     1,103       1,103
Unrealized gain (loss) on available-for-sale debt securities       (27)     (27)
Net loss         (11,920)   (11,920)
Balance at Dec. 31, 2021   $ 9 285,166 (91) (194,486)   90,598
Balance (in shares) at Dec. 31, 2021   8,722          
Vesting of RSU's     1       1
Vesting of RSU's (in shares)   4          
Share-based compensation     1,274       1,274
Unrealized gain (loss) on available-for-sale debt securities       (103)     (103)
Foreign currency translation adjustment             0
Net loss         (12,390)   (12,390)
Net loss including portion attributable to noncontrolling interest             (12,390)
Balance at Mar. 31, 2022   $ 9 286,441 (194) (206,876)   79,380
Balance (in shares) at Mar. 31, 2022   8,726          
Balance at Jun. 30, 2022   $ 9 287,619 (213) (223,930)   63,485
Balance (in shares) at Jun. 30, 2022 1 8,727          
Capital raise     1,151       1,151
Capital raise (in shares)   176          
Conversion of preferred stock to common stock (in shares) (1)            
Common stock issued - RubrYc transaction     650       650
Common stock issued - RubrYc transaction (in shares)   102          
Vesting of RSU's (in shares)   1          
Share-based compensation     1,222       1,222
Unrealized gain (loss) on available-for-sale debt securities       (10)     (10)
Net loss         (18,130)   (18,130)
Balance at Sep. 30, 2022   $ 9 290,642 (223) (242,060)   48,368
Balance (in shares) at Sep. 30, 2022   9,006          
Balance at Jun. 30, 2022   $ 9 287,619 (213) (223,930)   63,485
Balance (in shares) at Jun. 30, 2022 1 8,727          
Common stock issued - RubrYc transaction             650
Foreign currency translation adjustment             33
Net loss including portion attributable to noncontrolling interest             (58,977)
Balance at Mar. 31, 2023   $ 16 300,280   (282,907)   17,389
Balance (in shares) at Mar. 31, 2023   15,818          
Balance at Sep. 30, 2022   $ 9 290,642 (223) (242,060)   48,368
Balance (in shares) at Sep. 30, 2022   9,006          
Capital raise   $ 3 3,497       3,500
Capital raise (in shares)   3,366          
Cost to raise capital     (636)       (636)
Payment for fractional shares after reverse stock split     (39)       (39)
Payment for fractional shares after reverse stock split (in shares)   (8)          
Vesting of RSU's (in shares)   4          
Share-based compensation     1,127       1,127
Unrealized gain (loss) on available-for-sale debt securities       56     56
Net loss         (33,553)   (33,553)
Balance at Dec. 31, 2022   $ 12 294,591 (167) (275,613)   18,823
Balance (in shares) at Dec. 31, 2022   12,368          
Capital raise   $ 4 4,093       4,097
Capital raise (in shares)   3,422          
Vesting of RSU's (in shares)   28          
Share-based compensation     1,596       1,596
Unrealized gain (loss) on available-for-sale debt securities       113     113
Reclassification adjustment for loss on available-for-sale debt securities realized in net income       21     21
Foreign currency translation adjustment       $ 33     33
Net loss         (7,294)   (7,294)
Net loss including portion attributable to noncontrolling interest             (7,294)
Balance at Mar. 31, 2023   $ 16 $ 300,280   $ (282,907)   $ 17,389
Balance (in shares) at Mar. 31, 2023   15,818